Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 206,139,971 papers from all fields of science
Search
Sign In
Create Free Account
PAR-101
Known as:
PAR 101
, PAR101
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Tiacumicin B
Broader (1)
fidaxomicin
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
Fidaxomicin: A novel agent for the treatment of Clostridium difficile infection
G. Zhanel
,
A. Walkty
,
J. Karlowsky
The Canadian journal of infectious diseases…
2015
Corpus ID: 16494890
Oral vancomycin and oral metronidazole have several limitations with regard to their use in the treatment of Clostridium…
Expand
Review
2014
Review
2014
Fidaxomicin: a novel macrolide antibiotic for Clostridium difficile infection.
E. Chahine
,
A. Sucher
,
Karelee Mantei
The Consultant pharmacist : the journal of the…
2014
Corpus ID: 24780073
OBJECTIVE To review the chemistry, pharmacology, microbiology, pharmacodynamics, pharmacokinetics, clinical efficacy…
Expand
Review
2012
Review
2012
Fidaxomicin: a new option for the treatment of Clostridium difficile infection.
Alan P. Johnson
,
M. Wilcox
The Journal of antimicrobial chemotherapy
2012
Corpus ID: 14374596
The two drugs currently recommended for the treatment of Clostridium difficile infection (CDI), namely vancomycin and…
Expand
Review
2012
Review
2012
Fidaxomicin for the Treatment of Clostridium diffìcile Infections
C. Whitman
,
Quinn A. Czosnowski
The Annals of pharmacotherapy
2012
Corpus ID: 41118197
Objective: To evaluate the pharmacology, microbiology, safety, and efficacy of fidaxomicin for treatment of Clostridium difficile…
Expand
2010
2010
Effects of Inoculum, pH, and Cations on the In Vitro Activity of Fidaxomicin (OPT-80, PAR-101) against Clostridium difficile
F. Babakhani
,
J. Seddon
,
N. Robert
,
Y. Shue
,
P. Sears
Antimicrobial Agents and Chemotherapy
2010
Corpus ID: 19879220
ABSTRACT The effects of the inoculum, pH, cation concentrations, and different lots of commercial media on the in vitro…
Expand
Review
2010
Review
2010
Fidaxomicin: Difimicin; Lipiarmycin; OPT 80; OPT-80; PAR 101; PAR-101.
Drugs in R&D
2010
Corpus ID: 195684967
Fidaxomicin, an RNA polymerase inhibitor, is being developed by Optimer and Par Pharmaceuticals as a narrow-spectrum…
Expand
Review
2010
Review
2010
Fidaxomicin: A Macrocyclic Antibiotic for the Management of Clostridium difficile Infection
Karyn M. Sullivan
,
Linda M. Spooner
The Annals of pharmacotherapy
2010
Corpus ID: 25187935
Objective: To evaluate the efficacy and safety of fidaxomicin for the treatment of Clostridium difficile infection. Data Sources…
Expand
Review
2008
Review
2008
OPT-80, a macrocyclic antimicrobial agent for the treatment of Clostridium difficile infections: a review.
M. Gerber
,
G. Ackermann
Expert opinion on investigational drugs
2008
Corpus ID: 30922348
BACKGROUND Clostridium difficile-associated diarrhoea has become a major problem over the last years. Increasing incidence and…
Expand
Review
2008
Review
2008
OPT-80, a macrocyclic antimicrobial agent for the treatment of Clostridium difficile infections: a review
M. Gerber
,
G. Ackermann
2008
Corpus ID: 73312457
Background: Clostridium difficile-associated diarrhoea has become a major problem over the last years. Increasing incidence and…
Expand
Review
2007
Review
2007
Clostridium difficile: Recent Epidemiologic Findings and Advances in Therapy
Nicole L Mcmaster-Baxter
,
D. Musher
Pharmacotherapy
2007
Corpus ID: 16965567
Clostridium difficile–associated disease (CDAD) has become an important public health problem. The causative organism is acquired…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE